Wedbush has initiated coverage on CG Oncology Inc (CGON) with an Outperform rating, marking the firm's first assessment of the company's investment potential. This rating reflects Wedbush's analysis of CG Oncology's business model, industry dynamics, and growth prospects.
CG Oncology, headquartered in Irvine, California, is focused on developing and commercializing bladder-sparing therapies for patients with bladder cancer. The company’s lead product candidate, cretostimogene grenadenorepvec, is currently undergoing clinical trials for the treatment of non-muscle invasive bladder cancer (NMIBC). The BOND-003 trial is a Phase III study assessing the safety and efficacy of cretostimogene in patients who are high-risk and BCG-unresponsive. Additionally, CG Oncology is conducting the CORE-001 Phase II trial and the PIVOT-006 Phase III trial, further expanding its clinical portfolio.
As of December 9, 2025, CG Oncology's market capitalization stands at $3.5 billion, with an earnings per share (EPS) of -2.03. The company is expected to report its next earnings on August 6, 2026, with an EPS estimate of -0.72.
Analyst ratings like this one provide insight into the market's perception of a company's value, although they are based on estimates that may not always hold true. Investors are encouraged to consider various factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can also evolve as new information becomes available, highlighting the fluid nature of market assessments.